Major organ damage in SLE is caused by long-standing immunesuppressive therapy.
Several trials have failed in SLE due to disease heterogeneity and study design.
Rituximab is effective in refractory manifestations, especially LN.
B cells are still promising targets in SLE therapy.
Combination strategies are required to spare steroids and improve disease outcome.